RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Suzhou’s CStone Pharma announced its in-licensed product, Tibsovo (ivosidenib), produced a substantial improvement in progression-free survival in previously treated patients with cholangiocarcinoma. The results came from a US Phase III trial of Tibsovo conducted by Agios, a Boston area pharma and CStone’s partner. In June 2018, CStone acquired greater China rights to Tibsovo from Agios in a deal worth up to $424 million. Tibsovo is already approved in the US to treat acute myeloid leukemia (AML).
Source: China Biotoday
